Amneal Launches Aripiprazole Oral Solution, One Of The First Generic Liquid Forms Available For Abilify

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC (www.amneal.com) today announced the launch of aripiprazole oral solution in 1 mg/mL strength, allowing prescribers to continue writing for the recently discontinued reference brand.

“Healthcare providers can now continue prescribing a therapy they are comfortable with and in a form certain patients require”

The Amneal generic — one of the first liquid forms on the market — is an AA-rated, therapeutic equivalent to the discontinued Abilify® Oral Solution. It is now shipping in 150 mL (5 fl oz) bottles through wholesalers, distributors and directly to the trade.

“Healthcare providers can now continue prescribing a therapy they are comfortable with and in a form certain patients require,” explains Jim Luce, Amneal Executive Vice President of Sales & Marketing. “It’s a product that would otherwise be unavailable if not for the generic equivalent.”

Annual U.S. sales of aripiprazole oral solution were $62.8 million as of June 2015, according to IMS Health.

Visit https://prd02.apsiva.net/210/GenericCategory/Aripiprazole-pi.pdf for full prescribing information.

About Amneal Pharmaceuticals LLC

Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities — all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately held with U.S. headquarters in Bridgewater, New Jersey, and international headquarters in Zug, Switzerland. For more information, please visit www.amneal.com.

All trademarks are property of their respective owners.